AUTL News and Press, Autolus Therapeutics plc From 02/16/24

2024-02-16 07:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-08 11:29:12 ET More on Autolus Therapeutics Autolus Upgrades Leadership And Faces CAR-T Approval SA Analysts Comment On FDA Seeking Boxed Warning For CAR-T Cancer Therapies, Related Impact On AUTL Autolus Therapeutics: Pivotal Trial Using Familiar Approach, P...

2024-02-08 11:19:57 ET More on Autolus Therapeutics Autolus Upgrades Leadership And Faces CAR-T Approval SA Analysts Comment On FDA Seeking Boxed Warning For CAR-T Cancer Therapies, Related Impact On AUTL Autolus Therapeutics: Pivotal Trial Using Familiar Approach, P...

LONDON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten offering in the United States of 58,333,336 American Depositary Shar...

Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards market, pending market authorization BioNTech secures the right to utilize Autolus’ manufacturing capacity in ...

2024-02-06 09:52:32 ET Summary Obe-cel continues to demonstrate comparative efficacy with fewer side effects to approved therapies. Thus, the company will likely gain its first market authorization in November. Autolus made several strong leadership hires with direct experienc...

2024-01-23 10:30:09 ET The timing couldn't be odder for Autolus Therapeutics (AUTL). Just when the FDA agreed to review its CAR-T cancer therapy obe-cel and set an action date, the regulator also said separately that a serious warning had to be added to the prescribing information of CAR-T ...

LONDON, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in ACS Chemical Biology 1 entitled: ‘Designer small molecule ...

2024-01-22 07:20:26 ET More on Autolus Therapeutics Autolus Therapeutics: Pivotal Trial Using Familiar Approach, Possible Approval Coming Fast Autolus Therapeutics plc (AUTL) Q3 2023 Earnings Call Transcript Autolus Therapeutics plc 2023 Q3 - Results - Earnings Call ...

PDUFA Goal date is November 16, 2024 Company on track to submit a marketing authorization application to the European Medicines Agency (EMA) in the first half of 2024 LONDON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharma...